Plain-English translation of NCT07037901 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atopic Dermatitis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a new injectable medication designed to treat moderate-to-severe eczema in adults. Researchers want to find the right dose of this medication and learn whether it actually works better than a placebo (a dummy injection with no active drug). The study will follow patients for up to 48 weeks to measure how much their skin improves and whether the medication is safe.
Many people with severe eczema don't get enough relief from creams and lotions alone. This trial exists to see if this new treatment can help patients whose eczema hasn't responded to traditional topical therapies.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll receive subcutaneous injections (shots under the skin) — either the new medication or a placebo — on a schedule determined by the research team. You'll be randomly assigned to one of several groups testing different doses, so you won't know whether you're receiving the active medication or placebo. Some participants may start with placebo and switch to the active medication partway through. You'll visit the clinic regularly over 48 weeks so doctors can check your skin, measure your itching, and watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States